CXCL10 and breast carcinoma: While elements of this model are supported by direct patient data in OS (e.g., correlation between serum CXCL10 and metastasis and poor survival), the specific kinetic tracking of T-cell misdirection driven by the CXCL10 decoy gradient derive from established paradigms in melanoma and breast cancer biology and remains to be validated in OS models.